Lenvatinib for cell activation

Lenvatinib is a potent inhibitor of multiple receptor tyrosine kinases, with IC₅₀ values of  22 nM, 4 nM, 5.2 nM, 39 nM and 35 nM on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRβ and RET, respectively. It inhibits SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. Lenvatinib inhibits tumor growth in the human small cell lung cancer H146 xenograft model.

N/A

417716-92-8

426.85

Biochemicals

4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; E7080

C₂₁H₁₉ClN₄O₄

Crystalline solid

N/A

No

Yes

≥98% by HPLC

DMSO (>35 mg/ml)

-20°C

gel pack

36 months

Protect from air and light

cell

For cells, cell lines and tissues in culture till half confluency.